These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 16730273

  • 21. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):892-900. PubMed ID: 18245553
    [Abstract] [Full Text] [Related]

  • 22. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    Kijima I, Itoh T, Chen S.
    J Steroid Biochem Mol Biol; 2005 Dec 01; 97(4):360-8. PubMed ID: 16263272
    [Abstract] [Full Text] [Related]

  • 23. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R, Llombart-Cussac A, Lloveras B, Ramos M, Mayordomo JI, Fernández R, Tusquets I, Gil M, Barnadas A, Constenla M, Gilabert M, Alba E.
    Cancer; 2007 Nov 15; 110(10):2178-85. PubMed ID: 17926331
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR.
    Clin Cancer Res; 2001 Dec 15; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [Abstract] [Full Text] [Related]

  • 26. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
    Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK.
    Breast Cancer Res Treat; 2007 Nov 15; 106(1):75-84. PubMed ID: 17221152
    [Abstract] [Full Text] [Related]

  • 27. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, Dogliotti L, Berruti A.
    J Clin Oncol; 2006 Aug 01; 24(22):3623-8. PubMed ID: 16877730
    [Abstract] [Full Text] [Related]

  • 28. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK, Marquez-Garban DC, Pietras RJ.
    Drug Resist Updat; 2005 Aug 01; 8(4):219-33. PubMed ID: 16054421
    [Abstract] [Full Text] [Related]

  • 29. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A, Brodie AM, Njar VC.
    Cancer Res; 2006 Dec 01; 66(23):11485-93. PubMed ID: 17145897
    [Abstract] [Full Text] [Related]

  • 30. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J, Ellis P.
    Cancer Lett; 2007 Apr 18; 248(2):165-74. PubMed ID: 16919870
    [Abstract] [Full Text] [Related]

  • 31. Letrozole.
    Dellapasqua S, Colleoni M.
    Expert Opin Drug Metab Toxicol; 2010 Feb 18; 6(2):251-9. PubMed ID: 20095792
    [Abstract] [Full Text] [Related]

  • 32. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 33. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
    Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A.
    Cancer Res; 2006 Aug 01; 66(15):7775-82. PubMed ID: 16885381
    [Abstract] [Full Text] [Related]

  • 34. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep 01; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 35. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS, El-Hajj II, Makarem JA, Otrock ZK.
    Anticancer Drugs; 2006 Sep 01; 17(8):999-1002. PubMed ID: 16940812
    [Abstract] [Full Text] [Related]

  • 36. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R.
    Eur J Surg Oncol; 2008 Jul 01; 34(7):746-55. PubMed ID: 18296017
    [Abstract] [Full Text] [Related]

  • 37. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1285-91. PubMed ID: 16985247
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
    Salmon RJ, Alran S, Malka I, de Cremoux P, Rosty C, Languille O, Campana F, Breast Group of the Institut Curie, Sigal-Zafrani B.
    Am J Clin Oncol; 2006 Aug 20; 29(4):385-8. PubMed ID: 16891867
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.